This article is more than 5 years old. Information may no longer be current.

Sunrise's Hyperion in astigmatism trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FREMONT, Calif. — Preliminary clinical trials for the treatment of astigmatism appear promising for Sunrise Technologies' (NASDAQ: SNRS) Hyperion LTK System, company executives said. Trials are currently being conducted on patients outside the United States.

"The treatment algorithm performed as expected in the trials. The astigmatism reduction was in the proper axis and initial results of the clinical trials are promising. Patients are showing improved vision and no loss of best spectacle corrected visual acuity even at the 1 day and 2 week postoperative follow-up period," said Donald Sanders, MD, PhD, director for the Center of Clinical Research in Elmhurst, Ill.

The U.S. Food and Drug Administration approved the Hyperion LTK system last year for the temporary reduction of hyperopia. Supplemental labeling now says that, based upon existing information for the clinical parameters used in clinical trial, the company's model for the average longevity for the procedure indicates that some of the effect lasts 10 years and beyond, and that age-related drift toward hyperopia contributes to the loss of effect after the initial 2 years. Nomograms that are already in use outside the United States treat up to 5.625 D of hyperopia, and the effect can last longer than a patient's lifetime. Nomograms for treatment of astigmatism outside the United States are currently under development and human testing.